TriangleE7 TCR-T cells (NCT05686226)
E7 TCR-T cells trial for Cervical Cancer (NCT05686226). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or recurrent/refractory HPV16-positive cancer and HLA-A*02:01, after receiving or declining first-line therapy. Available first- and second-line standard options must be formally declined.
The idea: collect patients’ T cells and engineer them to recognize HPV16 E7 in tumors. After cyclophosphamide and fludarabine preparation, patients receive one intravenous E7 TCR-T infusion, followed by aldesleukin. Researchers measure tumor response and safety. The engineered cells aim to attack E7-bearing cancer cells.
This phase 2 study plans 20 patients. Christian Hinrichs leads through Rutgers; three US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.